Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$18.27 USD

18.27
1,428,571

+0.61 (3.45%)

Updated Nov 11, 2024 04:00 PM ET

After-Market: $18.27 0.00 (0.00%) 7:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.

Humana (HUM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Humana's (HUM) Q2 results are likely to reflect better revenues and membership growth.

Amneal (AMRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Amneal (AMRX) will provide financial updates when it reports second-quarter 2020 results.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) will provide financial updates when it reports second-quarter 2020 results.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Sorrento (SRNE) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

ACADIA (ACAD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

ACADIA's (ACAD) second-quarter 2020 results are likely to reflect lower revenues from Nuplazid due to the adverse impacts of COVID-19.

Axcella (AXLA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Axcella AXLA) will provide updates on its clinical programs when it releases second-quarter 2020 results.

Soleno (SLNO) to report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.

Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) will provide financial and corporate updates when it releases second-quarter 2020 results on Jul 30.

BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.

Emergent (EBS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

During Emergent's (EBS) upcoming Q2 earnings conference, investors will focus on the company's CDMO collaborations to help partners manufacture a vaccine against COVID-19.

Can Trikafta Drive Vertex's (VRTX) Revenues in Q2 Earnings?

by Zacks Equity Research

On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the sales performance of its newly-launched CF drug Trikafta and the anticipated impact of COVID-19 on sales.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.

Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More

by Zacks Equity Research

The biotech sector remains in focus with earnings, regulatory and other pipeline updates.

What to Expect for Applied Therapeutics (APLT) Q2 Earnings

by Zacks Equity Research

During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.

Is a Beat in Store for Translate Bio (TBIO) in Q2 Earnings?

by Zacks Equity Research

On Translate Bio's (TBIO) Q2 earnings call, investor focus will be on the company's progress with the development of its multiple COVID-19 vaccine candidates in collaboration with Sanofi.

Alimera (ALIM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.

Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Innoviva (INVA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

During Innoviva's (INVA) upcoming Q2 earnings call, investor focus will be on the royalties earned that comprise the company's top line.

ACADIA Files sNDA for Nuplazid in Dementia-Related Psychosis

by Zacks Equity Research

ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.

Why Is Acadia (ACAD) Down 7.6% Since Last Earnings Report?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com headshot

ACADIA to Merge Two Phase III Studies on Nuplazid for MDD

by Zacks.com

ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.